24 April 2018 — GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone…Original Article
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
